Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Singer

Showing results (81-90 of 313) with videos related to

Pageof 32
Sort By:
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA TrialShao-Wei Lo, Darae Ko, Dae Hyun Kim, et al.
Chest|September 24, 2004
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyDaniel E Singer, Gregory W Albers, James E Dalen, et al.
Archives of Internal Medicine|June 1, 2002
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumoniaEthan A Halm, Michael J Fine, Wishwa N Kapoor, et al.
Journal of the American Geriatrics Society|May 25, 2002
Community-acquired pneumonia and do not resuscitate ordersThomas J Marrie, Michael J Fine, Wishwa N Kapoor, et al.
Journal of General Internal Medicine|April 10, 2019
Disparities in Quality of Primary Care by Resident and Staff Physicians: Is There a Conflict Between Training and Equity?Utibe R Essien, Wei He, Alaka Ray, et al.
JAMA Internal Medicine|February 24, 2025
Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral AnticoagulantsClaire M Quinlan, Jerry Avorn, Aaron S Kesselheim, et al.
Annals of Internal Medicine|July 8, 2024
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort StudyTracey G Simon, Daniel E Singer, Yichi Zhang, et al.
BMJ (Clinical Research Ed.)|November 12, 2025
Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulationKueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, et al.
Circulation|March 4, 2009
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) studyAlan S Go, Margaret C Fang, Natalia Udaltsova, et al.
American Heart Journal|September 20, 2024
Assessing methods to ascertain persistence and adherence of oral anticoagulants in patients with atrial fibrillationAnran Tan, Sushama Kattinakere Sreedhara, Massimiliano Russo, et al.
Pageof 32

Showing results (81-90 of 313) with videos related to

Sort By:
Pageof 32
Medrxiv : the Preprint Server for Health Sciences|October 3, 2025
Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA TrialShao-Wei Lo, Darae Ko, Dae Hyun Kim, et al.
Chest|September 24, 2004
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyDaniel E Singer, Gregory W Albers, James E Dalen, et al.
Archives of Internal Medicine|June 1, 2002
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumoniaEthan A Halm, Michael J Fine, Wishwa N Kapoor, et al.
Journal of the American Geriatrics Society|May 25, 2002
Community-acquired pneumonia and do not resuscitate ordersThomas J Marrie, Michael J Fine, Wishwa N Kapoor, et al.
Journal of General Internal Medicine|April 10, 2019
Disparities in Quality of Primary Care by Resident and Staff Physicians: Is There a Conflict Between Training and Equity?Utibe R Essien, Wei He, Alaka Ray, et al.
JAMA Internal Medicine|February 24, 2025
Comparative Bleeding Risk in Older Patients With HIV and Atrial Fibrillation Receiving Oral AnticoagulantsClaire M Quinlan, Jerry Avorn, Aaron S Kesselheim, et al.
Annals of Internal Medicine|July 8, 2024
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort StudyTracey G Simon, Daniel E Singer, Yichi Zhang, et al.
BMJ (Clinical Research Ed.)|November 12, 2025
Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulationKueiyu Joshua Lin, Dae Hyun Kim, Daniel E Singer, et al.
Circulation|March 4, 2009
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) studyAlan S Go, Margaret C Fang, Natalia Udaltsova, et al.
American Heart Journal|September 20, 2024
Assessing methods to ascertain persistence and adherence of oral anticoagulants in patients with atrial fibrillationAnran Tan, Sushama Kattinakere Sreedhara, Massimiliano Russo, et al.
Pageof 32